T cell proliferative responses to hepatitis B virus-encoded envelope antigen (S + preS2 + preSj), recombinant core antigen (HBcAg), and natural hepatitis B e antigen (HBeAg) were examined in 22 HBeAg-positive patients with chronic type B hepatitis and 17 healthy hepatitis B surface antigen (HBsAg) carriers. The results showed that HBeAg-positive patients had (a) higher levels of T cell responses to HBcAg/HBeAg than those of healthy HBsAg carriers (P < 0.001 and P < 0.01, respectively); (b) a further increase in these T cell responses during acute exacerbations (P < 0.05 and P < 0.05, respectively); (c) subsidence in the T cell responses to HBcAg/HBeAg after recovery from acute exacerbations and HBeAg seroconversion, whereas the responses would persist at high levels if the patients did not enter a clinical remission; and (d) low levels of T cell responses to S + preS2 + preS, either before or after HBeAg seroconversion. The appearance of increasing T cell responses to HBcAg/HBeAg usually occurred in the early phase of acute exacerbations. These findings imply that HBcAg/HBeAg-specific T cells play an important role in the exacerbations of chronic hepatitis B and in HBeAg seroconversion. HBcAg/HBeAg-specific precursor T cell frequencies were serially studied in selected cases by limiting dilution assay. Elevation (two-to fourfold) of HBcAg/HBeAg-specific precursor T cell frequencies contributed to the increase of HBcAg/HBeAg-specific T cell proliferation during acute exacerbations. (J. Clin. Invest. 1992.89:87-96.)
most important etiology of cirrhosis and hepatocellular carcinoma in hyperendemic areas (1, 2) . Patients with chronic HBV infection can be generally divided into two groups: (a) those with chronic liver disease, usually referred to as having chronic type B hepatitis (CH-B); and (b) those without liver disease, referred to as being in an "inactive" or "healthy" hepatitis B surface antigen (HBsAg) carrier state (3) . In addition to elevated serum alanine aminotransferase (ALT) activities and detectable HBsAg in serum and liver, patients with CH-B have markers ofactive viral replication, such as hepatitis B e antigen (HBeAg) or HBV DNA in serum or hepatitis B core antigen (HBcAg) and HBeAg in the liver (4) . In contrast, healthy HBsAg carriers have HBsAg but without HBV DNA or HBeAg in serum, or detectable HBcAg and HBeAg in the liver. These carriers usually have normal serum ALT levels and no active inflammation or hepatocellular necrosis as revealed in liver biopsies (3) .
Studies on the natural history of chronic HBV infection (3, 5, 6) indicate that, except in some patients with point mutations of the pre-core (pre-C) region of the HBV genome (7, 8) , these two forms probably represent two stages of chronic HBV infection. Either spontaneously or during treatment, patients with CH-B can lose HBV DNA and HBeAg from serum and then have a remission. With subsequent appearance of antibody to HBeAg (anti-HBe), the disease usually evolves from chronic hepatitis to the healthy HBsAg carrier state. Seroconversion from HBeAg to anti-HBe is thus a "critical" event in the natural history of chronic HBV infection, and has been used as a major criterion for the success of interferon treatment (9) .
Although the clinicopathological and virological features of HBeAg seroconversion are well known (5, (10) (11) (12) (13) , the mechanisms of the seroconversion are still unclear. Circumstantial evidence indicates that HBV is not directly cytopathic for the infected hepatocytes, and that HBV-induced liver cell injury is mediated by an antiviral "cellular" immune response (14) (15) (16) . Because those who have cleared HBeAg frequently have temporary exacerbations ofhepatitis before the seroconversion, it has been suggested this event represents an "immune clearance" of hepatocytes containing actively replicating HBV as well as HBcAg/HBeAg (4, 17) . Furthermore, it has been demonstrated in a murine system that (a) the production of antibody against nonparticulate HBeAg is helper T cell dependent (18) , and (b) HBeAg, the nonparticulate form of HBcAg, is cross-reactive with HBcAg at the T-cell level, but antibodies against HBcAg do not cross-react with HBeAg (19) . Therefore, it is reasonable to infer that the HBeAg/HBcAg-specific T cells will play a key role in the modulation of acute exacerbation and HBeAg seroconversion. To test this hypothesis, we prospectively examined the T cell responses to HBV antigens and T cell precursor frequencies during acute exacerbations of CH-B. The results are then analyzed in relation to the HBeAg seroconversion.
Methods
Patients. At the National Taiwan University Hospital, in November 1988, 22 HBeAg-positive patients (16 men and 6 women, mean age 35 yr) with histologically proven CH-B were enrolled for this prospective study. 17 (21) .
DNA sequencing ofthe pre-C region. In two selected patients who had frequent exacerbations with high serum HBV DNA levels after HBeAg clearance and seroconversion, respectively, the pre-C region of HBV genome was directly sequenced by asymmetric polymerase chain reaction (PCR) (22) . The oligonucleotide primers hybridizing pre-C/ C sequences (5-GGAGGCTGTAGGCATAAATTGGTCTGCGC-3, 1776-1804) and (5-GATCTITCTGCGACGCGGCGATTGAGACC-3, 2428-2401) were used in the optimal ratio of 100:1. PCR was performed in a total volume of 100 ,l. The reaction mixture contained dNTPs 200MuM each, 1 X Taq polymerase buffer (67 mM Tris, pH 8.8, 16 mM (NH4)2 S04, 1.5 mM MgCl2, 10 mM 2-mercaptoethanol, 6.7 MM EDTA, 170 Mg/ml bovine serum albumin, 0.005% Tween 20, 0.005% NP-40), and 2.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT). 35 cycles of PCR were performed using a Perkin-Elmer Cetus apparatus, with denaturation at 940C, annealing of primers at 50'C, and extension at 680C for 1 min each. The single-strand HBV DNA of the PCR product was eluted from preparative 8% polyacrylamide gel electrophoresis (PAGE). The pre-C region was then sequenced directly by the dideoxy-chain termination method (23) with the second primer.
HBV antigens (Ag). (a) HBsAg: Plasma-derived HBsAg/adw particles were purified from HBeAg-positive patients by immunoaffinity chromatography as described previously (24) . Using mouse anti-preS2 and anti-preS2 monoclonal antibodies (MAbs; Institute of Immunology Co., Tokyo) and solid-phase ELISA, levels of preS, and preS2 in this Ag preparation were about 1% and 5% of total HBsAg reactivity, respectively. This Ag was referred to as S + preS2 + preS1 . (b) Recombinant (r) HBcAg: The Escherichia coli cells harboring a plasmid containing the core gene under the drive of XPL promoter were cultured in supplemented M9 minimum medium at 30'C until the density reached 0.3-0.5 of OD6w (25) . The incubation temperature was subsequently raised to 420C for 10 min and followed by 370C for another 3 h. After induction, the cell pellet was harvested by centrifugation and dissolved in sample buffer, rHBcAg protein was then eluted directly from a preparative SDS-PAGE and used as antigen after dialysis. Purity ofthis eluted rHBcAg was > 98% as determined by scanning densitometry of Coomassie Blue-stained SDS-PAGE. (c) Natural (n) HBeAg: Because recombinant HBeAg is not available, we decided to use nHBeAg in our experiments. Consequently, we purified HBeAg from pooled HBeAg-positive plasma by the method described previously (26-28) with some modifications ( At t PAGE was performed in 12.5% for rHBcAg, 15% for nHBeAg, and HBsAg. The rabbit polyclonal anti-HBc and mouse monoclonal anti-HBe/a + antiHBe/b antibodies were used for Western blot analysis of rHBcAg and nHBeAg, respectively. Only SDS-PAGE with silver stain was shown for HBsAg. M, molecular weight markers; c, rHBcAg; e, nHBeAg; S. major protein of HBsAg-the band of lower molecular weight is nonglycosylated form of HBsAg, P24, and the higher, glycosylated from of HBsAg, GP27; 52, pre S2. Lane 1, before induction; lane 2, after induction.
T Cell Response in Hepatitis B e Antigen Seroconversion 89 CO2. On day 6, 20 U of recombinant human interleukin 2 (Genzyme Corp., Boston, MA) was added to each well and on day 9, 50% of the medium in each well was removed and replaced with fresh complete medium and 5% IL-2. On day 12, cultures were incubated with [3H]-thymidine (I uCi per well) and harvested 18 h later for measurement of incorporated radioactivity by liquid scintillation counting. For each set of 24 replicates, antigen-containing cultures were scored as positive if the proliferative response was greater than the mean + 3 SD ofcontrol cultures without antigen. The percentage of negative cultures was used to determine the precursor frequency according to the Poisson distribution and the x2 minimization (32) .
Statistics. Statistic analysis was done by using x2 test, Fisher's exact test, Student's t test, paired t test, and the correlation coefficiency for linear regression. Kinetic analysis and precursor frequency determinations were performed by the statistical methods of x2 minimization (32) . When the data showed P > 0.05, the relationship between responder cell dose and the number of nonresponding wells (FO) was considered consistent with a single-hit kinetic model. The precursor frequency (f) is equivalent to the slope of the regression line. 
Results
Initial study ofTcellproliferative responses to HB VAg. HBeAg seroconversion, and 6 also had a clinical remission. During acute exacerbations, all of these 10 patients showed a prominent increase in the peak levels of T cell proliferation to rHBcAg (SI = 6.31±2.83) and to nHBeAg (SI = 6.12±3.70) (Fig. 3) , but not to S + preS2 + preS1 (SI = 1.32±0.44). The difference of peak levels of T cell responses to rHBcAg and nHBeAg was not statistically significant (P > 0.05). No linear correlation was noted between the peak serum ALT levels and the peak levels of T cell responses to rHBcAg or nHBeAg (data not shown).
In general, the onsets of peak levels of T cell responses to HBcAg/HBeAg were usually coupled with the onsets of peak serum ALT levels (Table II) . However, the detectable increasing levels of the HBcAg/HBeAg-specific proliferation usually appeared before the onsets of peak serum ALT levels, i.e., occurred in the early phase of acute exacerbations. The data suggest that T cell responses increase at a time before or simultaneously with the hepatitis activity.
Of the 14 episodes of acute exacerbations, there was no significant difference in the peak levels of T cell responses to rHBcAg and to nHBeAg between the eight episodes followed by HBeAg clearance and the other six episodes without HBeAg clearance (abortive seroconversion) (Table II) .
On follow-up, those six patients (patients 1, 4, 5, 6, 7, 8; Table II ) having a clinical remission also showed a significant decrease in the levels of T cell responses to rHBcAg and nHBeAg 3-6 mo after HBeAg seroconversion. Some of them had a decrease of T cell responses down to the levels of the healthy HBsAg carriers 6-9 mo after remission from acute exacerbations. A typical case (patient 8) is depicted in Fig. 4 (top) . Patients 9 and 10 remained HBeAg positive after acute exacerbations. Their T cell responses to both rHBcAg and nHBeAg persisted at high levels associated with fluctuating serum ALT levels. Despite HBeAg seroclearance and further follow-up for 14 Expressed by stimulation index. § Depicted in Fig. 4 .
Before the onset of peak serum ALT levels in acute exacerbation. After the onset of peak serum ALT levels in acute exacerbation. increase in T cell responses to rHBcAg and nHBeAg (Fig. 4,  bottom) . The pre-C region of HBV genome in these two HBeAg-negative patients was sequenced. No point mutation at the initiation codon of the pre-C region was detected. None of the 17 healthy carriers developed HBV reactivations during the follow-up period. No significant changes in T cell responses to HBV Ag were detected. The healthy HBsAg carriers with positive T cell responses to HBV Ag on initial study became unresponsive on follow-up.
HB VAg-specificprecursor Tcellfrequency analysis. To further explore the possible mechanisms of changes in T cell responses to HBV Ag in the course of acute exacerbations, six selected cases including four CH-B patients and two healthy carriers of HBsAg were studied by LDA to determine the HBV Ag-specific precursor T cell frequencies. Three of the four CH-B patients developed acute exacerbations, one of them followed by HBeAg seroconversion and clinical remission, whereas another patient remained unchanged in clinical status during follow-up. The two healthy HBsAg carriers were stable and asymptomatic and had normal liver tests on follow-up. The results of initial and follow-up LDA were shown in Table  III . There was no significant difference between CH-B patients and healthy carriers of HBsAg in the frequencies of S + preS2 + preSI-specific precursor T cells (-1/105) . However, the rHBcAg/nHBeAg-specific precursor T cell frequencies of CH-B patients were significantly higher than those of healthy carriers (P < 0.05, two-sided t test performed on geometric means). During acute exacerbations, rHBcAg/nHBeAg-specific precursor T cell frequencies were elevated to two-to fourfold ofthe original levels (P < 0.01, paired t test), but S + preS2 + preS,-specific precursor T cell frequencies remained unchanged. Fig. 5 shows the serial follow-up of standard LDA plots of case 4 in Table III . 6 mo after seroconversion to antiHBe and clinical remission, his rHBcAg/nHBeAg-specific precursor T cell frequencies decreased to two to three cells per 1O' T cells, approximating to the levels of healthy HBsAg carriers. Worthy of note is that nHBeAg-specific precursor T cell frequencies in cases 1 and 3 were higher than rHBcAg-specific precursor T cell frequencies during acute exacerbations. were ranked as follows: -, undetectable; +, 1-10 pg/ml; ++, 10-100 pg/ml; +++, 100-1,000 pg/ml; ++++, > 1,000 pg/ml. Underlined values indicate significant changes in precursor T cell frequencies between initial and follow-up studies. (16, 19) . In Taiwan, a hyperendemic area ofHBV infection, the vast majority of patients with HBeAg-positive CH-B were born to HBeAg-positive mothers and infected in the neonatal or perinatal period at that time their T cells were probably tolerant to HBeAg (34). Milich and co-workers (35) have suggested that "HBeAg," a secreted protein, may cross the placenta and circulate to the fetal thymus where through a mechanism of thymic education leads to the functional deletion or inactivation of major histocompatibility complex class II-restricted helper T cells in utero resulting in host tolerance specific for the HBcAg/ HBeAg. But the HBcAg/HBeAg-specific host tolerance is reversible. In the absence (or decrease in the level) of tolerogen (i.e., HBeAg), new HBcAg/HBeAg-specific thymocytes can emerge from the thymus, and this HBcAg/HBeAg-specific T cell "repertoire renewal process" requires -13-16 wk in the murine model. In humans, we propose that once the level of HBeAg (tolerogen) declines to a threshold not sufficient to maintain the tolerance status, the HBcAg/HBeAg-specific T cell repertoire renewal process may be initiated even in the presence of HBeAg. Indeed, it is during the low replicative phase when the HBeAg (tolerogen) levels are lowering, the CH-B patients are attacked by a series of relapses and remissions associated with histologic signs of chronic active liver disease (10, 11 Responder dose x 10 CH-B c AE CH-B c R Figure 5 . Serial follow-up study of HBV Ag-specific precursor T cell frequencies of case 4 in Table III . CH-B, chronic type B hepatitis; AE, acute exacerbation; R, HBeAg seroconversion and clinical remission.
study that acute exacerbation in CH-B is temporally correlated with the elevated T cell responses to rHBcAg/nHBeAg and with the increase of rHBcAg/nHBeAg-specific precursor T cell frequencies.
Compatible with the results from the study using recombinant HBeAg in acute and chronic hepatitis B (33), the levels of T cell responses to nHBeAg were also slightly lower than to rHBcAg during acute exacerbations in CH-B. The reasons may be due to the conformational features of rHBcAg, which could be more efficiently internalized and then presented by antigenpresenting cells ( 18) , and partly due to the presence of HBcAgspecific T cell epitopes within the 39 amino acids unique for HBcAg at the carboxyl terminus. Nevertheless, some patients had higher levels of T cell responses to nHBeAg than to rHBcAg and have more prominent increase in the nHBeAgspecific precursor T cell frequencies than that of rHBcAg. This suggests that the additional 10 NH2-terminal amino acids present only within the nHBeAg (37, 38) probably contain an HBeAg-specific T cell epitope and can contribute to the antigen recognition by T cells during the course of HBeAg seroconversion.
After HBeAg seroconversion, most patients with CH-B will resolve into healthy HBsAg carrier state. No more active HBV replication is detected and the T cell responses to rHBcAg/nHBeAg will decline gradually to a level equivalent to that in healthy HBsAg carriers. However, despite seroconversion, there is one group of patients whose hepatitis continues to progress, accompanied by high levels of HBV DNA in the serum (39 (G -) A) at nucleotide 1896 in the pre-C region of HBV genome precluding secretion of HBeAg in seven out of eight patients with anti-HBe-positive CH-B. In the present study, one patient with active HBV replication after HBeAg seroconversion, and another in the window period, were examined for their pre-C sequences. No point mutation at position 1896 was found. Therefore, after HBeAg seroconversion it is not known whether anti-HBe-positive patients with point mutations at pre-C region of HBV genome have the same patterns of T cell responses to HBV antigens as those without pre-C point mutation. Additional studies are apparently needed.
Although increased HBcAg/HBeAg-specific T cell responses are closely related to hepatitis activity, the mechanism responsible for exacerbation of CH-B is not yet settled. It is necessary to study whether or not there is increase in the HBcAg/HBeAg-specific T cell population in the liver. In fact, Ferrari and co-workers (40) isolated lymphocytes from diagnostic liver biopsies of CH-B patients and successfully established and characterized polyclonal HBcAg-specific CD4' and CD8' T cell lines; but no HBsAg-specific cell lines could be identified. It implies that these intrahepatic nucleocapsid Agspecific T cells may be responsible for mediating hepatitis activities, and very likely reflects in the increased T rHBcAg/nHBeAg in the peripheral blood. They have subsequently cloned one of these lines to produce four CD4' T-cell clones that undergo class II-restricted proliferation in response to HBcAg and are capable ofproviding antigen-specific help to autologous B cells producing anti-HBc (41). However, whether or not these HBcAg-specific T cell clones are cross-reactive with the natural HBeAg and are able to provide an antigen-specific help to produce anti-HBe has not yet been clarified. Thus, to explore further the immune mechanisms ofHBeAg seroconversion in chronic HBV infection, functional studies of HBcAg/HBeAg-specific T cell clones generated from the inflammatory infiltrate in the liver and analysis oftheir fine specificities as well as T cell receptor gene usages are ongoing in our laboratories.
